
Nice backs Novartis’ lung cancer drug
pharmafile | May 20, 2016 | News story | | NHS, NICE, Novartis, ceritinib, lung cancer, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) has recommended Novartis’ (VTX: NOVN) Ceritinib (zykadia) as a treatment for lung cancer.
Ceritinib has marketing authorisation in the UK as a treatment for anaplastic lymphoma kinase (ALK) positive advanced non-small-cell lung cancer (NSCLC). Ceritinib is an ALK inhibitor.
The company submission stated that the NHS list price is £4,923.45 for a 30-day supply.
Lung cancer is the third most common cancer in the UK (2013), accounting for 13% of all new cases. It is the second most common cancer in both males (14% of all male cases) and females (12% of all female cases).
In 2013, there were 45,525 new cases of lung cancer in the UK: 24,481 (54%) in males and 21,044 (46%) in females. The crude incidence rate shows that there are 78 new lung cancer cases for every 100,000 males in the UK, and 65 for every 100,000 females.
Anjali Shukla
Related Content

“That gap between innovation and delivery was what stood out to me most”
Pharmafile chats with Camunda’s Natosha McNeal about the vital role of delivery, onboarding AI and …

Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study
People in their forties account for almost three-quarters of those who do not attend NHS …

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for …






